These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 27111901)

  • 21. Ipilimumab: from preclinical development to future clinical perspectives in melanoma.
    Letendre P; Monga V; Milhem M; Zakharia Y
    Future Oncol; 2017 Mar; 13(7):625-636. PubMed ID: 27882779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer Mutational Load: The More the Merrier for Immune Checkpoint Blockade Therapies.
    EBioMedicine; 2016 Nov; 13():1-2. PubMed ID: 27916137
    [No Abstract]   [Full Text] [Related]  

  • 23. The role of talimogene laherparepvec (T-VEC) in the age of checkpoint inhibitors.
    Andtbacka RH
    Clin Adv Hematol Oncol; 2016 Aug; 14(8):576-9. PubMed ID: 27487099
    [No Abstract]   [Full Text] [Related]  

  • 24. Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomas.
    Kasenda B; Kühnl A; Chau I
    Expert Rev Hematol; 2016; 9(2):123-35. PubMed ID: 26581237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
    Rojas JJ; Sampath P; Hou W; Thorne SH
    Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Future directions for checkpoint inhibition in melanoma.
    Hamid O
    Clin Adv Hematol Oncol; 2016 Feb; 14(2):85-6. PubMed ID: 27057805
    [No Abstract]   [Full Text] [Related]  

  • 27. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system.
    Pico de Coaña Y; Choudhury A; Kiessling R
    Trends Mol Med; 2015 Aug; 21(8):482-91. PubMed ID: 26091825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Checkpoint inhibitors in the treatment of brain metastases of non-small-cell lung cancer and melanoma.
    Kourie HR; Kanaan H; Awada G; Awada AH
    Future Oncol; 2017 May; 13(12):1097-1103. PubMed ID: 28326837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Harnessing the immune system for the treatment of melanoma: current status and future prospects.
    Guennoun A; Sidahmed H; Maccalli C; Seliger B; Marincola FM; Bedognetti D
    Expert Rev Clin Immunol; 2016 Aug; 12(8):879-93. PubMed ID: 27070898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
    Villasboas JC; Ansell S
    Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune Checkpoint Therapy and the Search for Predictive Biomarkers.
    Sharma P
    Cancer J; 2016; 22(2):68-72. PubMed ID: 27111900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune modulation in cancer with antibodies.
    Page DB; Postow MA; Callahan MK; Allison JP; Wolchok JD
    Annu Rev Med; 2014; 65():185-202. PubMed ID: 24188664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy: Going Beyond Local Control.
    Schoenhals JE; Seyedin SN; Tang C; Cortez MA; Niknam S; Tsouko E; Chang JY; Hahn SM; Welsh JW
    Cancer J; 2016; 22(2):130-7. PubMed ID: 27111909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation.
    Blank CU
    Curr Opin Oncol; 2014 Mar; 26(2):204-14. PubMed ID: 24424272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis.
    Pasquali S; Chiarion-Sileni V; Rossi CR; Mocellin S
    Cancer Treat Rev; 2017 Mar; 54():34-42. PubMed ID: 28189914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.
    Kroon P; Gadiot J; Peeters M; Gasparini A; Deken MA; Yagita H; Verheij M; Borst J; Blank CU; Verbrugge I
    Cancer Immunol Immunother; 2016 Jun; 65(6):753-63. PubMed ID: 27160390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms.
    Monteiro ID; Califano R; Mountzios G; de Mello RA
    Future Oncol; 2016 Feb; 12(4):551-64. PubMed ID: 26776915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune Checkpoint Inhibitors in Organ Transplant Patients.
    Kittai AS; Oldham H; Cetnar J; Taylor M
    J Immunother; 2017 Sep; 40(7):277-281. PubMed ID: 28719552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging Immunotargets and Immunotherapies in Prostate Cancer.
    Montironi R; Santoni M; Sotte V; Cheng L; Lopez-Beltran A; Massari F; Matrana MR; Moch H; Berardi R; Scarpelli M
    Curr Drug Targets; 2016; 17(7):777-82. PubMed ID: 26898309
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in the Immunobiological Therapies for Advanced Melanoma.
    Pérez Gago MC; Saavedra Santa Gadea O; de la Cruz-Merino L
    Actas Dermosifiliogr; 2017 Oct; 108(8):721-728. PubMed ID: 28388991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.